Literature DB >> 11600735

Outcome measures in Sjögren's syndrome.

K H Asmussen, S J Bowman.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11600735     DOI： 10.1093/rheumatology/40.10.1085

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  6 in total

1.  EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome.

Authors:  Raphaèle Seror; Philippe Ravaud; Simon J Bowman; Gabriel Baron; Athanasios Tzioufas; Elke Theander; Jacques-Eric Gottenberg; Hendrika Bootsma; Xavier Mariette; Claudio Vitali
Journal:  Ann Rheum Dis       Date:  2009-06-28       Impact factor: 19.103

2.  [Sjögren's syndrome. Current aspects from a rheumatological point of view].

Authors:  C Tomiak; T Dörner
Journal:  Z Rheumatol       Date:  2006-10       Impact factor: 1.372

3.  Lamivudine is not effective in primary Sjögren's syndrome.

Authors:  B Gescuk; A J Wu; J P Whitcher; T E Daniels; S Lund; K Fye; J C Davis
Journal:  Ann Rheum Dis       Date:  2005-02-11       Impact factor: 19.103

4.  Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren's syndrome.

Authors:  J-E Gottenberg; M Busson; J Cohen-Solal; F Lavie; K Abbed; R P Kimberly; J Sibilia; X Mariette
Journal:  Ann Rheum Dis       Date:  2005-01-07       Impact factor: 19.103

5.  Increased risk of primary Sjögren's syndrome in female patients with thyroid disorders: a longitudinal population-based study in Taiwan.

Authors:  Ming-Chi Lu; Wen-Yao Yin; Tzung-Yi Tsai; Malcolm Koo; Ning-Sheng Lai
Journal:  PLoS One       Date:  2013-10-18       Impact factor: 3.240

6.  Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial.

Authors:  Peter Willeke; Bernhard Schlüter; Heidemarie Becker; Heiko Schotte; Wolfram Domschke; Markus Gaubitz
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.